Navigation Links
Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
Date:5/8/2008

ward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
(Date:7/10/2014)... 10, 2014   Ceres, Inc . (Nasdaq: ... announced today financial results for the three months ended ... business. Ceres reported that the company and ... this growing season in Brazil, which concluded in June, ... sorghum evaluation areas for part of the growing season. ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... Mich., Sept. 23 Sanford Rose Associates®-Rochester, an ... Rose Associates® network of offices, was recently named ... Sanford Rose Associates®-Rochester was established in January 2009 ... professional searches in the automotive, alternative energy, defense, ...
... BEACH, Calif., Sept. 23 Genesis Biopharma, Inc. (OTC Bulletin ... cancer therapies, today announced that it has closed a private ... accredited investors to purchase 933,341 shares of its common stock ... Series A warrants to purchase 466,674 shares at an exercise ...
... Association (BMA) Award Winning Medical Authors and Editors -- LONDON, September 23, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:Genesis Biopharma Announces $700K Private Financing 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 3Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 4Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 5Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 6Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 7Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 8
(Date:7/11/2014)... is creating a new professorship in tissue engineering ... for Molecular Engineering and the Marine Biological Laboratory, ... Millicent and Eugene Bell Foundation., The Eugene Bell ... Institute for Molecular Engineering. That endowed chair holder ... MBL,s Eugene Bell Center for Regenerative Biology and ...
(Date:7/11/2014)... 2014---A team of researchers from The Chinese University of ... gene of wild soybean linked to salt tolerance, with ... saline soil. This study published online in Nature ... genomic information for crop improvement. , Soybean is an ... human selection, cultivated soybeans have less genetic diversities than ...
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2Molecular snapshots of oxygen formation in photosynthesis 2
... Mich. Ask any political leader if they are ... typically a resounding, "Yes." Evaluating its effectiveness, however, ... and environmental science and policy professor at Michigan State ... evaluate sustainability at a national gathering of scientists Feb. ...
... NC How did early humans adapt to different climates and ... the globe? And what does that mean for humans living today? ... and anthropology will present their findings on Sunday February 20th at ... titled "Humans Without Borders: Evolutionary Processes at Work In Humans ...
... At this year,s American Association for the Advancement ... to 21, Caltech researchers will present topics ranging from ... in bioengineering. Caltech,s Alice S. Huang, AAAS president, ... highlighting this year,s AAAS theme, "Science Without Borders." ...
Cached Biology News:It's time to take a unified approach toward measuring sustainability 2Panelists to discuss evolution of human brain size, skin color and diet at AAAS meeting 2Tip sheet: Caltech researchers presenting at AAAS 2Tip sheet: Caltech researchers presenting at AAAS 3
... dihydrochloride) is a fluorescent counterstain ... in color. The bright blue ... red fluorochromes such as rhodamine, ... DAPI can be used for ...
... 20-HETE is a cytochrome P450 (CYP450) ... in the renal and cerebral vasculature. In ... that mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is ... concentration of free 20-HETE (20-40 pg/ml in ...
... rapidly and reliably amplify unknown genomic DNA ... provides hassle-free, ready-to use components, at an ... provided in each kit. The Genome Walking ... localized cloning of genomic DNA, isolating promoter ...
Mol wt: average mol wt16,951.27 Da by calculation...
Biology Products: